Search | Clinical Trials Finder

Conditions: Central Retinal Vein Occlusion
Interventions: Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy; Biological
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Choroidal Neovascularization, Age-related Macular Degeneration
Interventions: hI-con1, ranibizumab, Sham injection; Biological · Other
Lead sponsor: Iconic Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 48
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more

Conditions: Keratoconus
Interventions: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment; Combination Product
Lead sponsor: Epion Therapeutics; Industry
Eligibility: 8 Years to 45 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Rowland Heights, California • San Francisco, California • Miami, Florida + 10 more

Conditions: Stargardt's Macular Dystrophy
Interventions: avacincaptad pegol, Sham; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more

Conditions: Choroideremia
Interventions: BIIB111; Genetic
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more

Conditions: Geographic Atrophy
Interventions: Sham, Lampalizumab; Other · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 36
States / cities: Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions: Ultevursen, Sham-procedure; Drug · Other
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 12 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Miami, Florida + 7 more

Conditions: Branch Retinal Vein Occlusion
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 26
States / cities: Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more

Conditions: Diabetes Mellitus, Diabetic Macular Edema
Interventions: ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection; Drug · Other
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more

Conditions: Vitreomacular Adhesion Including Macular Hole
Interventions: Ocriplasmin, Sham injection; Drug · Other
Lead sponsor: ThromboGenics; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 22 more

Conditions: Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions: sepofarsen, Sham; Drug · Other
Lead sponsor: ProQR Therapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Age-Related Macular Degeneration
Interventions: E10030, bevacizumab or aflibercept, E10030 sham injection; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 100
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more

Conditions: Wet Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 59
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more

Conditions: Type 1 Diabetes, Celiac Disease
Interventions: Gluten Challenge, Sham Challenge; Dietary Supplement
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: Oculeve Intranasal, Sham, Oculeve Extranasal; Device
Lead sponsor: Oculeve, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Waterbury, Connecticut • Norfolk, Virginia

Conditions: Keratoconus
Interventions: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment; Combination Product
Lead sponsor: Epion Therapeutics; Industry
Eligibility: 8 Years to 45 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • Tucson, Arizona • Murrieta, California + 9 more

Conditions: Postoperative Pain, Acute
Interventions: Active Pulsed Shortwave Treatment with BioElectronics Model 088, Sham Treatment; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Macular Edema Secondary to Inflammation
Interventions: KSI-101, Sham Comparator; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 55
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 47 more

Conditions: Non Arteritic Anterior Ischemic Optic Neuropathy
Interventions: QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg, Sham Injection Procedure; Drug · Other
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 44
States / cities: Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 35 more

Conditions: Diabetic Macular Edema (DME)
Interventions: UBX1325, Sham; Drug · Other
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Bakersfield, California • Encino, California + 15 more

Conditions: Central Retinal Vein Occlusion
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions: Ixo-vec, Aflibercept; Genetic · Drug
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 79
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more

Conditions: Asthma in Children
Interventions: Bi-level Positive Airway Pressure, Sham Bi-level Positive Airway Pressure; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 17 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes

A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Pulsed Electromagnetic Fields for Postoperative Analgesia: A Randomized, Triple-Masked, Sham-Controlled Pilot Study

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial